Scientific Publications

TCR 

IL-12

CAR-T

TCR

May 16, 2022

American Society for Gene and Cell Therapy (ASGCT) 2022

Stem-cell memory TCR-T cells targeting hotspot EGFR, KRAS and p53 neoantigens generated through co-expression of membrane-bound Interleukin-15

November 13, 2021

Society for Immunotherapy of Cancer (SITC) 2021

“Neoantigen-specific TCR-T cells targeting shared hotspot mutations for adoptive cell therapy in common epithelial cancers.”

SUBJECT: TCR

June 9, 2021

2021 Development of Sleeping Beauty Transposed TCR-T Cells for Adoptive Cell Therapy of Cancer

Drew Deniger, Vice President of Immunology, presentation at the Federation of American Societies for Experimental Biology (FASEB) virtual conference held on Wednesday June 9, 2021, entitled “Development of Sleeping Beauty Transposed TCR-T Cells for Adoptive Cell Therapy of Cancer”

SUBJECT: TCR

April 12, 2021

2021 Annual Meeting for American Association for Cancer Research (AACR)

Hotspot mutations in KRAS and TP53 targeted by TCR-T cells genetically modified with the Sleeping Beauty transposon/transposase system.

SUBJECT: TCR

December 8, 2019

61st American Society of Hematology (ASH) Annual Meeting & Exposition, Orlando

Rapid Personalized Manufacture (RPM) of Sleeping Beauty System-generated NY-ESO-1-specific TCR-T Cells Co-expressing Membrane-bound IL-15 Yields Antitumor Responses

SUBJECT: TCR

June 16, 2016

The American Society of Gene & Cell Therapy

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System

SUBJECT: TCR

Back to TOP

IL-12

November 19, 2021

2021 Society for Neuro-Oncology (SNO) Annual Meeting

Final Resultsof Controlled IL-12 Monotherapy and in Combination with PD-1 Inhibitor in Adult Subjects with Recurrent Glioblastoma.

SUBJECT: IL-12

November 19, 2020

2020 Society for Neuro-Oncology (SNO) Annual Meeting

Phase 2 Trial of Controlled IL-12 in Combination with PD-1 Inhibitor in Adult Subjects with Recurrent Glioblastoma.

SUBJECT: IL-12

Combination of Controlled Interleukin-12 Gene Therapy with Immune Checkpoint Blockade in Recurrent Glioblastoma: Updated Results of a Multi-Institutional, Open Label Phase 1 Trial.

SUBJECT: IL-12

Phase I/II Study of Controlled IL-12 as Immunotherapy for Diffuse Intrinsic Pontine Glioma (DIPG).

SUBJECT: IL-12

May 29, 2020

2020 American Society of Clinical Oncology (ASCO) Annual (Virtual) Meeting

Survival of Subjects with Recurrent Glioblastoma Receiving Intratumoral Administration of Controlled IL-12 with Limited Exposure to Dexamethasone

SUBJECT: IL-12

Final Results of Controlled IL-12 Monotherapy in Adults with Grade III or IV Gliomas

SUBJECT: IL-12

November 23, 2019

2019 Annual Meeting of the Society for Neuro-Oncology (SNO) in Phoenix

Survival of Subjects with Recurrent Glioblastoma Receiving Intra-tumoral Administration of IL-12 Managed with Low-dose Dexamethasone

SUBJECT: IL-12

PD-1 Inhibition can be Combined with IL-12 in Subjects with Recurrent Glioblastoma

SUBJECT: IL-12

August 14, 2019

Science Translational Medicine

Regulatable Interleukin-12 Gene Therapy in Patients With Recurrent High-Grade Glioma: Results of a Phase 1 Trial

SUBJECT: IL-12

June 02, 2019

2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago

Evaluation of Controlled IL-12 as Monotherapy in Subjects with Recurrent GBM

SUBJECT: IL-12

Evaluation of Controlled IL-12 in Combination with PD-1 Inhibitor in Subjects with Recurrent GBM

SUBJECT: IL-12

November 16, 2018

23rd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) in New Orleans

A Phase 1 study of Ad-RTS-hIL-12 + veledimex in adults with recurrent glioblastoma: Dose determination with updated overall survival

SUBJECT: IL-12

June 01, 2018

2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL

Demonstration of anti-tumor immunity via intratumoral regulated platform Ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients

SUBJECT: IL-12

May 14, 2018

Cancer Gene Therapy

Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for treatment of glioma

SUBJECT: IL-12

October 10, 2016

European Society for Medical Oncology (ESMO) 2016 Congress

Phase 1b/2 study of intratumoral Ad-RTS-hIL-12+veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer

SUBJECT: IL-12

September 16, 2015

CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival

Demonstration of systemic antitumor immunity via intratumoral regulated expression of IL-12 in advanced breast cancer and melanoma patients

SUBJECT: IL-12

December 01, 2014

AACR Special Conference

Ad-RTS-hIL-12 + Veledimex Regulation of IL-12 Expression in Advanced Breast Cancer and Melanoma

SUBJECT: IL-12

May 21, 2013

2013 Annual Meeting of the American Society of Clinical Oncology (ASCO

A Phase I Open-Label Study of Ad-RTS-hIL-12, an Adenoviral Vector Engineered to Express hIL-12, in Combination with an Oral Activator Ligand in Subjects with Unresectable Stage III/IV Melanoma

SUBJECT: IL-12

May 15, 2013

ASGCT Annual Meeting 2013

Nonclinical and Phase I Clinical Studies with a Regulated Adenoviral Gene Delivery of IL-12 Show Promising Clinical Activity in Unresectable Stage III/IV Melanoma

SUBJECT: IL-12

Back to TOP

CAR-T

March 12, 2020

Letters to Blood
Long-term outcomes of Sleeping Beauty generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

SUBJECT: CAR-T

February 12, 2018

Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond in Keystone, Colorado

Rapid production of T-cells co-expressing CAR and membrane-bound IL-15 potentiates antitumor activity and promotes invivo memory (poster)

SUBJECT: CAR-T

December 09, 2017

59th American Society of Hematology (ASH) Annual Meeting and Exposition, Atlanta

Long-term follow up after adoptive transfer of CD19-specific CAR+T cells genetically modified via non-viral Sleeping Beauty system following hematopoietic stem cell transplantation (HSCT)

SUBJECT: CAR-T

CD19-specific chimeric antigen receptor-modified T cells with safety switch produced under “Point-Of-Care” using the Sleeping Beauty system for the very rapid manufacture and treatment of B-cell malignancies

SUBJECT: CAR-T

Autologous T cells modified to co-express CD33-specific chimeric antigen receptor and a kill switch for treatment of CD33+ acute myeloid leukemia

SUBJECT: CAR-T

Shortening the time to manufacture CAR+T cells with Sleeping Beauty system supports T-cell engraftment and anti-tumor effects in patients with refractory CD19+ tumors

SUBJECT: CAR-T

September 1, 2016

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

Clinical data from first generation CD19-specific CAR-T cells, manufactured using Sleeping Beauty gene transfer, administered to ALL and NHL patients undergoing HSCT.  Read more

SUBJECT: CAR-T

December 07, 2015

American Society of Hematology Annual Meeting

Pre-emptive infusion with CD19-directed, CAR-modified T cells infused after autologous or allogeneic hematopoietic cell transplantation for patients with advanced CD19+ malignancies

SUBJECT: CAR-T

Back to TOP